Citadel Advisors
MAIA icon

Citadel Advisors’s MAIA Biotechnology MAIA Stock Holding History

Citadel Advisors’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,749
Closed -$52.2K – 14956
2024
Q1 		$52.2K Sell
23,749
-33,724
-59% -$50.6K ﹤0.01% 12138
2023
Q4 		$67.2K Buy
+57,473
New +$92.8K ﹤0.01% 11437
2023
Q3 		– Sell
-23,387
Closed -$51.5K – 14757
2023
Q2 		$51.5K Buy
+23,387
New +$62.6K ﹤0.01% 11765

Other funds holding MAIA

HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

Citadel Advisors's MAIA Position: Q2 2024 in Review

Citadel Advisors sold out of MAIA Biotechnology (MAIA) in Q2 2024, closing a stake of 23,749 shares — an estimated $52.2K sold.

Citadel Advisors first reported a position in MAIA in Q2 2023 and held it in 3 quarters. The position peaked at $67.2K in Q4 2023. 21 funds tracked by Wall St. Rank hold MAIA as of Q2 2024.

  • Citadel Advisors reported no remaining MAIA Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 23,749 MAIA Biotechnology shares in Q2 2024, an estimated $52.2K.
  • Citadel Advisors first reported a position in MAIA Biotechnology in Q2 2023 and held it in 3 quarters.
  • Citadel Advisors's MAIA Biotechnology position peaked at $67.2K in Q4 2023.
  • 21 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.